Log In
BCIQ
Print this Print this
 

NT-104

  Manage Alerts
Collapse Summary General Information
Company Kanion Pharmaceutical Co. Ltd.
DescriptionOral small molecule inhibitor of epidermal growth factor receptor (EGFR) and EGFR2
Molecular Target Epidermal growth factor receptor (EGFR) ; Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionEpidermal growth factor (EGF) receptor inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
PartnerNewGen Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/02/2012

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today